{
      "Rank": 990,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Patient: Intravenous infusion of single-dose of Mesenchymal stem cells (MSCs)",
            "Intravenous infusion of single-dose of Ringer's lactate, albumin and heparin solution"
      ],
      "ArmGroupInterventionName": [
            "Biological: Mesenchymal stem cell",
            "Other: Placebo"
      ],
      "ArmGroupLabel": [
            "Treatment",
            "Placebo"
      ],
      "ArmGroupType": [
            "Experimental",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT05433298"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "The purpose of this study is evaluate the feasibility, safety and potential efficacy of an advanced cell therapy product for the treatment of patients with SARS-CoV-2 pneumonia."
      ],
      "BriefTitle": [
            "Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19."
      ],
      "CentralContactEMail": [
            "paulo.brofman@pucpr.br",
            "carmen.rebelatto@pucpr.br"
      ],
      "CentralContactName": [
            "Paulo R Brofman, phD",
            "Carmen K Rebelatto, phD"
      ],
      "CentralContactPhone": [
            "+554132711858",
            "+554132711858"
      ],
      "CentralContactPhoneExt": [
            "1858",
            "1858"
      ],
      "CentralContactRole": [
            "Contact",
            "Contact"
      ],
      "CollaboratorClass": [
            "OTHER_GOV"
      ],
      "CollaboratorName": [
            "Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico"
      ],
      "CompletionDate": [
            "December 31, 2022"
      ],
      "CompletionDateType": [
            "Anticipated"
      ],
      "Condition": [
            "COVID-19 Pneumonia",
            "COVID-19"
      ],
      "ConditionAncestorId": [
            "D000012141",
            "D000007239",
            "D000011024",
            "D000014777",
            "D000018352",
            "D000003333",
            "D000030341",
            "D000012327",
            "D000008171",
            "D000012140"
      ],
      "ConditionAncestorTerm": [
            "Respiratory Tract Infections",
            "Infections",
            "Pneumonia, Viral",
            "Virus Diseases",
            "Coronavirus Infections",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC01",
            "BC08",
            "All",
            "BC23"
      ],
      "ConditionBrowseBranchName": [
            "Infections",
            "Respiratory Tract (Lung and Bronchial) Diseases",
            "All Conditions",
            "Symptoms and General Pathology"
      ],
      "ConditionBrowseLeafAsFound": [
            "COVID-19",
            "Pneumonia"
      ],
      "ConditionBrowseLeafId": [
            "M2562",
            "M13056",
            "M9435",
            "M14130",
            "M5520",
            "M13066",
            "M16674",
            "M19643",
            "M5707",
            "M22838",
            "M14301",
            "M10320",
            "M14129"
      ],
      "ConditionBrowseLeafName": [
            "COVID-19",
            "Pneumonia",
            "Infections",
            "Respiratory Tract Infections",
            "Communicable Diseases",
            "Pneumonia, Viral",
            "Virus Diseases",
            "Coronavirus Infections",
            "Coronaviridae Infections",
            "Nidovirales Infections",
            "RNA Virus Infections",
            "Lung Diseases",
            "Respiratory Tract Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000086382",
            "D000011014"
      ],
      "ConditionMeshTerm": [
            "COVID-19",
            "Pneumonia"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Forty patients with COVID-19 will receive an intravenous infusion of one dose of 1.000.000 umbilical cord mesenchymal cells per kilo of the patient. Twenty patients will receive a placebo (Ringer's lactate solution, albumin and heparin). Conventional treatment will be performed together with the infusion of cells, during the study period. The evaluation times will be at pre-infusion, 6 and 24 hours, days 5 and 28, 3 and 6 months. The patient exams performed: serology, biochemistry, blood count and blood gas analysis, metabolomics/proteomics, antibody evaluation, electrocardiogram, CT-scan and X-ray, cytokines, viral load, cytometry, and clinical evaluation. The patients will be evaluated all the time, during hospitalization period, to assess adverse events."
      ],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nBoth sexes;\naged 18 to 79 years old;\nhospitalized patients;\nradiological diagnosis of viral pneumonia;\nvirological diagnosis of SARS-CoV-2 infection;\nwith noninvasive ventilatory support;\nC-reactive protein and ferritin above the reference value considered normal;\nassent confirmed to participate in the study.\n\nExclusion Criteria:\n\nContraindications for use of corticosteroids;\nimmunosuppressive, cytotoxic and antiviral treatment, experimental medications and chronic corticosteroid use;\nmorbid obesity (BMI> 35);\nmultiple organ dysfunction syndrome;\npre-malignant neoplastic conditions with life expectancy lower than 1 year old;\npre-existing chronic illnesses like chronic dialysis kidney disease, chronic liver disease, congestive heart failure Class IV; pulmonary hypertension (WHO Class III/IV);\npre-existing or current thromboembolic pathology;\ntransplanted patients;\npre-existing severe allergic reaction;\nhistory of HIV and tuberculosis;\nenrollment in another clinical trial;\npregnancy or breastfeeding."
      ],
      "EnrollmentCount": [
            "60"
      ],
      "EnrollmentType": [
            "Anticipated"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Treatment",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [
            "PhSol",
            "All",
            "FiAg",
            "AnCoag"
      ],
      "InterventionBrowseBranchName": [
            "Pharmaceutical Solutions",
            "All Drugs and Chemicals",
            "Fibrinolytic Agents",
            "Anticoagulants"
      ],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [
            "M21013",
            "M8731",
            "M45326"
      ],
      "InterventionBrowseLeafName": [
            "Pharmaceutical Solutions",
            "Heparin",
            "Calcium heparin"
      ],
      "InterventionBrowseLeafRelevance": [
            "low",
            "low",
            "low"
      ],
      "InterventionDescription": [
            "Administration of advanced cell product",
            "Ringer's lactate, albumin and heparin solution"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Mesenchymal stem cell",
            "Placebo"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "No"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "June 27, 2022"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 23, 2022"
      ],
      "LeadSponsorClass": [
            "OTHER"
      ],
      "LeadSponsorName": [
            "Paulo Brofman"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Curitiba"
      ],
      "LocationContactEMail": [
            "paulo.brofman@pucpr.br",
            "carmen.rebelatto@pucpr.br"
      ],
      "LocationContactName": [
            "Paulo R Brofman, phD",
            "Carmen L\u00facia K Rebelatto, phD",
            "Paulo R Brofman, phD"
      ],
      "LocationContactPhone": [
            "+554132711858",
            "+554132711858"
      ],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [
            "Contact",
            "Contact",
            "Principal Investigator"
      ],
      "LocationCountry": [
            "Brazil"
      ],
      "LocationFacility": [
            "Paulo Roberto Slud Brofman"
      ],
      "LocationState": [
            "Paran\u00e1"
      ],
      "LocationStatus": [
            "Recruiting"
      ],
      "LocationZip": [
            "80215200"
      ],
      "MaximumAge": [
            "79 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "Multicenter Phase I/IIa Study of Mesenchymal Stromal Cells for the Treatment of Patients With SARS-CoV-2 Pneumonia."
      ],
      "OrgClass": [
            "OTHER"
      ],
      "OrgFullName": [
            "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1"
      ],
      "OrgStudyId": [
            "MSC SARS-CoV-2"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1"
      ],
      "OverallOfficialName": [
            "Paulo R Brofman, phD"
      ],
      "OverallOfficialRole": [
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Recruiting"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 1",
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "November 26, 2022"
      ],
      "PrimaryCompletionDateType": [
            "Anticipated"
      ],
      "PrimaryOutcomeDescription": [
            "The primary expected outcome is the safety and tolerability of using intravenously infused UTC-MSC suspension in patients with pneumonia caused by SARS-CoV-2. This outcome will be evaluated by recording adverse events that must be reported throughout the study period."
      ],
      "PrimaryOutcomeMeasure": [
            "Safety of intravenously infused UCT-MSC suspension"
      ],
      "PrimaryOutcomeTimeFrame": [
            "After first cell infusion until the end of study. The clinical follow-up of patients will be one year after the transplant."
      ],
      "ReferenceCitation": [
            "Rebelatto CLK, Senegaglia AC, Franck CL, Daga DR, Shigunov P, Stimamiglio MA, Marsaro DB, Schaidt B, Micosky A, de Azambuja AP, Leit\u00e3o CA, Petterle RR, Jamur VR, Vaz IM, Mallmann AP, Carraro Junior H, Ditzel E, Brofman PRS, Correa A. Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial. Stem Cell Res Ther. 2022 Mar 21;13(1):122. doi: 10.1186/s13287-022-02796-1.",
            "Senegaglia AC, Rebelatto CLK, Franck CL, Lima JS, Boldrini-Leite LM, Daga DR, Leit\u00e3o CA, Shigunov P, de Azambuja AP, Bana E, Marsaro DB, Schaidt B, Micosky A, Jamur VR, Schluga Y, Vaz IM, Ribeiro LL, Correa A, Brofman EPRS. Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report. Cell Transplant. 2021 Jan-Dec;30:9636897211021008. doi: 10.1177/09636897211021008."
      ],
      "ReferencePMID": [
            "35313959",
            "34074163"
      ],
      "ReferenceType": [
            "result",
            "result"
      ],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [
            "Pontif\u00edcia Universidade Cat\u00f3lica do Paran\u00e1"
      ],
      "ResponsiblePartyInvestigatorFullName": [
            "Paulo Brofman"
      ],
      "ResponsiblePartyInvestigatorTitle": [
            "Principal Investigator"
      ],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor-Investigator"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [
            "U1111-1267-1200",
            "31935420.7.1001.0020"
      ],
      "SecondaryIdDomain": [
            "UTN - WHO International Clinical Trials Registry Platform",
            "CAAE - Certificado de Apresenta\u00e7\u00e3o para Aprecia\u00e7\u00e3o \u00c9tica"
      ],
      "SecondaryIdLink": [],
      "SecondaryIdType": [
            "Other Identifier",
            "Other Identifier"
      ],
      "SecondaryOutcomeDescription": [
            "Evaluation of lung function.",
            "Evaluation of pulmonary function using breathing chest radiography. Assessment of peripheral opacities, interstitial and airspace opacities, diffuse airspace opacities, interstitial opacities, lobar consolidation, atelectasis, cavities, pulmonary cysts, and emphysema.",
            "Distance covered by the patient in a period of 6 minutes.",
            "Analysis of ventilatory parameters and arterial blood gas analysis.",
            "D-dimer, C-reactive protein, erythrocyte sedimentation rate, ferritin, creatine, urea, saline, potassium, bilirubin, total protein and fractions, albumin, globulin, oxalacetic transaminase, pyruvic transaminase, lactate dehydrogenase, creatine phosphokinase, troponin I, coagulogram.",
            "Red blood cells, hemoglobin, hematocrit, total leukocytes, basophil, eosinophil, neutrophil, lymphocytes, monocytes, platelets.",
            "Expression of the RpRd gene.",
            "Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL) -2, IL-6, IL-7, IL-8, tumor necrosis factor (TNF) \u03b1, monocyte chemoattractant protein-1 (MCP1/CCL2) and macrophage inflammatory protein 1-alpha (MIP1a/CCL3).",
            "Evaluation of hospitalization days.",
            "Chest computed tomography evaluation will analyze the following characteristics: ground glass opacities, linear opacities, consolidation, interlobular septal thickening, crazy-paving pattern, subpleural lines, bronchial wall thickening, lymph node enlargement and pleural effusion. Lesions will quantify by assigning a score to all abnormal areas involved. Each lobe will assigned a score of 0 (0% involvement), 1 (1-25% involvement), 2 (26-50% involvement), 3 (51-75% involvement) or 4 (76%-100% involvement). The total score will be the sum of all lobes, ranging from 0 to 25.",
            "Clinical evaluation of patients.",
            "Evaluation of the number of patients who died during the study."
      ],
      "SecondaryOutcomeMeasure": [
            "Pulmonary function test to evaluate the improvement of respiratory function",
            "Radiography to evaluate the improvement of respiratory function",
            "6-minute walk to evaluate the improvement of respiratory function",
            "Decrease on days of non-invasive mechanical ventilation",
            "Biochemical tests to evaluate the improvement of laboratory parameters",
            "Blood count to evaluate the improvement of laboratory parameters",
            "Viral load to evaluate the improvement of laboratory parameters",
            "Cytokine dosage to evaluate inflammatory parameters",
            "Decrease in hospital stay",
            "Computed tomography score to evaluate the improvement of pulmonary function",
            "Reduction in the percentage of intubated patients",
            "Decrease in mortality"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Pre-infusion, on days 5 and 28, 3 and 6 months.",
            "Pre-infusion, on days 5 and 28, 3 and 6 months.",
            "Pre-infusion, on days 5 and 28, 3 and 6 months.",
            "Six hours after infusion, days 1, 5 and 28, 3 and 6 months.",
            "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
            "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
            "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
            "Pre-infusion, on days 1, 5 and 28, 3 and 6 months.",
            "From admission to discharge, or a maximum of 6 months.",
            "Pre-infusion, on days 5 and 28, 3 and 6 months.",
            "After first cell infusion until six months after the transplant.",
            "After first cell infusion until the end of study. The clinical follow-up of patients will be six months after the transplant."
      ],
      "SeeAlsoLinkLabel": [
            "UC-MSCs infusion is safe and can play an important role as an adjunctive therapy, both in the early stages, preventing severe complications and in the chronic phase with postacute sequelae reduction in critically ill COVID-19 patients.",
            "The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2."
      ],
      "SeeAlsoLinkURL": [
            "https://pubmed.ncbi.nlm.nih.gov/35313959/",
            "https://pubmed.ncbi.nlm.nih.gov/34074163/"
      ],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "May 1, 2022"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2022"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "June 27, 2022"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "May 19, 2022"
      ],
      "StudyFirstSubmitQCDate": [
            "June 23, 2022"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}